Abstract 699P
Background
As COVID-19 will likely became an epidemic disease, vaccination planning will be crucial for LS-mLC receiving anti-cancer therapy (ACT) in order to prolong effective immunity
Methods
According to the timing of BD and Sars-Cov2 infection (Cov-I) during oncological history, LC pts were allocated in three cohorts: A) Cov-I before PV or third BD; B) uninfected who completed PV during ACT; C) uninfected LC who had completed PV before cancer diagnosis and will receive BD after stating of ACT. As control cohorts, we included other cancer patients (mOC pts) who had completed PV and were candidate to BD during myelosuppressive (cohort D) or not-myelosuppressive (cohort E) ACT. The primary endpoints were seroprevalence of IgG Anti-spike-RBD (anti-S IgG) at two pre-defined time-points (T1: +30-90 days after BD; T2: + 6 months +/- 4 weeks after BD). As exploratory endpoint, we compared median pre-vaccination value of four cytokines (IL-6, IL-2R, TNF-α, IL-10) with post-BD values in immunotherapy-treated pts (IT-pts)
Results
Between October 2021 and February 2022, 113 LS-mLC patients were assigned in cohort A (20 pts), in cohort B (61 pts) or in cohort C (32 pts); 55 LS-mOC patients were allocated in cohort D (25 pts) and in cohort E (30 pts). Throughout the Omicron variant spread, 40 pts (24%) experienced Cov-I before T2 evaluation. Anti-S IgG qualitative seropositivity rate was 100% at T1 and 98.8% at T2. After 6-months FU, hybrid immunization (Cov-I before or after BD), was associated with higher median anti-S IgG trier compared to vaccine alone-induced immunity (p = <0.0001). In uninfected pts, median anti-S IgG titre was significantly lower in IT-treated patients compared to non-IT treated patients (p = 0.02); no difference was found when comparing myelosuppressive or not ACT. Among 68 IT-pts, 5 pts (7.3%) showed significant increase (≥ 1.5 fold) of at least two cytokines in post-BD samples, without reporting ir-AE
Conclusions
Administration BDs of COVID-19 mRNA vaccine in LS-mLC pts resulted effective and safe. In IT-pts without recent Cov-I, additional BDs should be considered to prolong serological immunity
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fondazione Policlinico Universitario A Gemelli-IRCCS.
Funding
Grant Award: Vaccinazione Anti-COVID-19 Nei Pazienti Oncologici, Sponsor: AIOM (Associazione Italiana di Oncologia Medica)/FICOG (Federation of Italian Cooperative Oncology Groups).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
668P - Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer
Presenter: Alexander Drilon
Session: Poster session 17
669P - Patient-reported outcomes with selpercatinib in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial
Presenter: Hyunseok Kang
Session: Poster session 17
670P - Preliminary efficacy and safety of tinengotinib (TT-00420) monotherapy in Chinese patients (pts) with advanced solid tumors: Results from a phase Ib/II study
Presenter: Panpan Zhang
Session: Poster session 17
671P - Safety and efficacy of PM060184 plus gemcitabine in advanced solid tumors
Presenter: Sanjay Goel
Session: Poster session 17
672P - Phase I/II trial of RVU120 (SEL120), CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors
Presenter: Rafal Dziadziuszko
Session: Poster session 17
673P - A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours
Presenter: Patrick Schoeffski
Session: Poster session 17
674P - Response of thrombopoietin receptor agonists in MDM2 inhibitor induced thrombocytopenia
Presenter: Raymond DeMatteo
Session: Poster session 17
675P - A phase I study of safety, pharmacokinetics, and pharmacodynamics of SCR-6920, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced malignant tumors
Presenter: Jinming Yu
Session: Poster session 17
676P - Preclinical characterization of novel peptide binders for EphA2-targeted radiopharmaceutical therapy
Presenter: Renee Clift
Session: Poster session 17
677P - Preliminary findings from a phase I, open-label, dose-finding study of SNB-101 in patients with advanced solid tumors
Presenter: Yun Beom Sang
Session: Poster session 17